Previous studies demonstrated that POLE mutants are associated with improved clinical outcomes in various types of malignancy that were explained by enhanced host immune responses and increased sensitivity to anticancer drugs in colorectal and endometrial cancers [10,31]. The gene discussed is POLE; the disease is endometrial cancer.